Tracer library / [177Lu]Lu-DOTA-POL3026

[177Lu]Lu-DOTA-POL3026

Also written as [Lu-177]Lu-DOTA-POL3026

Radionuclide: Lu-177 t½ 9584.6 min
Modality: Therapy
Production route: —
Stage: Reported once
Syntheses indexed: 1

Glioma and brain tumours Preclinical only, no clinical indication yet

What it is

Compound class: DOTA-conjugated CXCR4-targeting peptide
Target / mechanism: CXCR4 (C-X-C chemokine receptor 4) PMID 39008219
Clinical application: Preclinical targeted radionuclide therapy (TRT) for glioblastoma PMID 39008219
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	none	>95%	>95%	DOTA-POL3026 CSBio, California, US	39008219 2024 EJNMMI Radiopharm Chem [177Lu]LuCl3 was added to the DOTA-conjugated peptides in 0.15 M NaOAc buffer, pH 4.7, with a total reaction volume of 0.25–0.35 mL, and reacted at 95 °C for 30 min with gentle shaking - All three DOTA-conjugated peptides could be radiolabelled with 177Lu with > 95% radiochemical yield.

Precursor

Common precursor: —
Suppliers seen in the literature: —
Cited suppliers in indexed syntheses: CSBio
Typical final purification: —

Need this precursor?We can point you to suppliers for [177Lu]Lu-DOTA-POL3026, or handle the enquiry for you.

Get in touch

Notes

Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 39008219. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 39008219: 'DOTA-CTCE9908, DOTA-DV1-K-DV3, and DOTA-POL3026 were obtained from the custom peptide synthesis service of CSBio (California, US)'.